We are live on
!
Find out more
BBA
Baker Bros. Advisors Portfolio holdings
AUM
$20B
1-Year Est. Return
154.41%
This Fund
S&P 500
This Quarter
Est. Return
+3.34%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$17.4B
AUM Growth
+$71.8M
(+0.42%)
Cap. Flow
-$218M
Cap. Flow
% of AUM
-1.26%
Top 10 Holdings %
Top 10 Hldgs %
90.2%
Holding
115
New
7
Increased
18
Reduced
11
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Roivant Sciences
ROIV
|
+$27.7M |
| 2 |
AbCellera Biologics
ABCL
|
+$26.2M |
| 3 |
Ultragenyx Pharmaceutical
RARE
|
+$23.1M |
| 4 |
Denali Therapeutics
DNLI
|
+$21.2M |
| 5 |
Monte Rosa Therapeutics
GLUE
|
+$12.2M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
argenx
ARGX
|
+$63.1M |
| 2 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
+$55.9M |
| 3 |
DICE
DICE Therapeutics, Inc. Common Stock
DICE
|
+$48.1M |
| 4 |
IMGN
Immunogen Inc
IMGN
|
+$28.7M |
| 5 |
AnaptysBio
ANAB
|
+$12.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.2% |
| 2 | Miscellaneous | 0.79% |
| 3 | Financials | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Fate Therapeutics
FATE
$277M
| – | – |
-1,671,717
| Closed | -$7.96M |
|
|
KYNB
102
Kyntra Bio
KYNB
$32.3M
| – | – |
-9,523
| Closed | -$643K |
|
103
MacroGenics
MGNX
$255M
| – | – |
-892,579
| Closed | -$4.78M |
|
|
MREO
104
Mereo BioPharma
MREO
$44.7M
| – | – |
-3,554,979
| Closed | -$4.69M |
|
105
Nkarta
NKTX
$208M
| – | – |
-271,329
| Closed | -$594K |
|
106
Spyre Therapeutics
SYRE
$7.99B
| – | – |
-136,404
| Closed | -$1.54M |
|
107
Vera Therapeutics
VERA
$2.53B
| – | – |
-146,464
| Closed | -$2.35M |
|
108
Verastem
VSTM
$663M
| – | – |
-1,336,485
| Closed | -$9.94M |
|
|
VINC
109
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
| – | – |
-11,279
| Closed | -$293K |
|
|
IMGN
110
DELISTED
Immunogen Inc
IMGN
| – | – |
-1,520,097
| Closed | -$28.7M |
|
|
ARAV
111
DELISTED
Aravive, Inc. Common Stock
ARAV
| – | – |
-3,261,224
| Closed | -$4.11M |
|
|
KDNY
112
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| – | – |
-1,455,202
| Closed | -$55.9M |
|
|
DICE
113
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| – | – |
-1,035,786
| Closed | -$48.1M |
|
Similar funds
ASRS
FWIA
CWP
SFA
MGP
JAM
Baker Bros. Advisors's Q3 2023 Portfolio in Review
As of Q3 2023, Baker Bros. Advisors held 115 positions worth $17.4B, up 0.42% from $17.3B the previous quarter. Its ten largest holdings account for 90% of the portfolio.
Baker Bros. Advisors's Q3 2023 filing shows 7 new, 18 increased, 11 reduced and 14 closed positions. Its largest new stake was Morphic Holding, Inc. Common Stock: 215,800 shares worth $4.94M. The largest sale was argenx, an estimated $63.1M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous and Financials.
- Baker Bros. Advisors's largest Q3 2023 buy was Morphic Holding, Inc. Common Stock: 215,800 shares worth $4.94M.
- Baker Bros. Advisors added most to Roivant Sciences in Q3 2023, an estimated $27.7M increase.
- Baker Bros. Advisors's biggest Q3 2023 reduction was argenx, cutting an estimated $63.1M.
- Baker Bros. Advisors fully exited Chinook Therapeutics, Inc. Common Stock in Q3 2023, selling an estimated $55.9M.
- Baker Bros. Advisors's ten largest holdings make up 90% of its $17.4B portfolio in Q3 2023.
- Baker Bros. Advisors opened 7 new positions and closed 14 in Q3 2023.
- Baker Bros. Advisors's portfolio value rose 0.42% quarter-over-quarter to $17.4B.
Based on Baker Bros. Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.